NO20003256D0 - ACE inhibitor-MMP inhibitor kombinasjoner - Google Patents

ACE inhibitor-MMP inhibitor kombinasjoner

Info

Publication number
NO20003256D0
NO20003256D0 NO20003256A NO20003256A NO20003256D0 NO 20003256 D0 NO20003256 D0 NO 20003256D0 NO 20003256 A NO20003256 A NO 20003256A NO 20003256 A NO20003256 A NO 20003256A NO 20003256 D0 NO20003256 D0 NO 20003256D0
Authority
NO
Norway
Prior art keywords
inhibitor
combinations
mmp
ace
ace inhibitor
Prior art date
Application number
NO20003256A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003256L (no
Inventor
Jr Joseph Thomas Peterson
Milton Lethan Pressler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22083543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20003256(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20003256L publication Critical patent/NO20003256L/no
Publication of NO20003256D0 publication Critical patent/NO20003256D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20003256A 1997-12-23 2000-06-22 ACE inhibitor-MMP inhibitor kombinasjoner NO20003256D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6859497P 1997-12-23 1997-12-23
PCT/US1998/023993 WO1999032150A1 (en) 1997-12-23 1998-11-10 Ace inhibitor-mmp inhibitor combinations

Publications (2)

Publication Number Publication Date
NO20003256L NO20003256L (no) 2000-06-22
NO20003256D0 true NO20003256D0 (no) 2000-06-22

Family

ID=22083543

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003256A NO20003256D0 (no) 1997-12-23 2000-06-22 ACE inhibitor-MMP inhibitor kombinasjoner

Country Status (24)

Country Link
US (1) US6133304A (ja)
EP (1) EP1047450B1 (ja)
JP (1) JP2001526245A (ja)
KR (1) KR20010033473A (ja)
AR (1) AR015504A1 (ja)
AT (1) ATE225187T1 (ja)
AU (1) AU751701B2 (ja)
BR (1) BR9814422A (ja)
CA (1) CA2305436A1 (ja)
CO (1) CO4970775A1 (ja)
DE (1) DE69808518T2 (ja)
DK (1) DK1047450T3 (ja)
ES (1) ES2184340T3 (ja)
HU (1) HUP0100427A3 (ja)
IL (1) IL135428A0 (ja)
IS (1) IS5446A (ja)
NO (1) NO20003256D0 (ja)
NZ (1) NZ503962A (ja)
PE (1) PE20000065A1 (ja)
PL (1) PL341335A1 (ja)
PT (1) PT1047450E (ja)
UY (1) UY25321A1 (ja)
WO (1) WO1999032150A1 (ja)
ZA (1) ZA9811794B (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1362951A (zh) * 1999-03-03 2002-08-07 宝洁公司 二杂－取代的金属蛋白酶抑制剂
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
ES2376161T3 (es) 2001-01-29 2012-03-09 Janssen Pharmaceuticals, Inc. Indoles sustituidos y su utilización como antagonistas de integrinas.
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
US20040242694A1 (en) * 2001-08-20 2004-12-02 Yasuki Kihara Remedial agent for cardiac failure
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
EP1545287B1 (en) * 2002-10-04 2012-12-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Vasoregulating compounds and methods of their use
US7462593B2 (en) * 2002-11-07 2008-12-09 Us Gov Health & Human Serv Compositions and methods for promoting angiogenesis
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2534352A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
WO2005048985A2 (en) * 2003-11-14 2005-06-02 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
AU2005221151A1 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
US20080269282A1 (en) * 2004-08-02 2008-10-30 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
AU2009259839A1 (en) * 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US20110082114A1 (en) * 2009-10-01 2011-04-07 Symphony Evolution, Inc. Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors
EP3243515B1 (en) 2011-08-30 2019-10-16 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9884085B2 (en) 2013-06-26 2018-02-06 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
SG11201700341PA (en) 2014-07-17 2017-02-27 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders
US20190008828A1 (en) 2015-12-28 2019-01-10 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527879B1 (en) * 1990-05-11 1997-02-05 Pfizer Inc. Synergistic therapeutic compositions and methods
WO1996024373A2 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist
DK0901466T3 (da) * 1996-05-17 2002-02-18 Warner Lambert Co Biphenylsulfonamid-matriksmetalloproteinase-inhibitorer
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
AU1522099A (en) 1999-07-12
PL341335A1 (en) 2001-04-09
NZ503962A (en) 2002-03-28
US6133304A (en) 2000-10-17
WO1999032150A1 (en) 1999-07-01
PT1047450E (pt) 2003-02-28
PE20000065A1 (es) 2000-02-11
DE69808518D1 (de) 2002-11-07
NO20003256L (no) 2000-06-22
EP1047450A1 (en) 2000-11-02
IS5446A (is) 2000-04-14
UY25321A1 (es) 2004-07-30
CA2305436A1 (en) 1999-07-01
HUP0100427A3 (en) 2002-11-28
DK1047450T3 (da) 2003-01-27
AU751701B2 (en) 2002-08-22
JP2001526245A (ja) 2001-12-18
KR20010033473A (ko) 2001-04-25
ES2184340T3 (es) 2003-04-01
HUP0100427A2 (hu) 2001-06-28
BR9814422A (pt) 2000-10-10
ZA9811794B (en) 1999-06-29
IL135428A0 (en) 2001-05-20
CO4970775A1 (es) 2000-11-07
DE69808518T2 (de) 2003-06-26
EP1047450B1 (en) 2002-10-02
ATE225187T1 (de) 2002-10-15
AR015504A1 (es) 2001-05-02

Similar Documents

Publication Publication Date Title
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
NO995433D0 (no) Protease-inhibitorer
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
ID19198A (id) Inhibitor metaloprotease heterosiklik
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
DK0936906T3 (da) Refluxhæmmere
ID18416A (id) Inhibitor metaloprotease diheterosiklik
NO20003256D0 (no) ACE inhibitor-MMP inhibitor kombinasjoner
FI963597A (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
NO982686L (no) R°rledningsplugg
FI972160A (fi) Matriisimetalloproteaasi-inhibiittorit
NO995434L (no) Proteaseinhibitorer
NO995435D0 (no) Protease-inhibitorer
NO995268D0 (no) Proteaseinhibitorer
ID18417A (id) Inhibitor ditentat metaloprotease
ID17792A (id) Penghambat penghambat metaloproreinase matriks
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
NO20001835D0 (no) WOF inhibitor
DE69828361D1 (de) Apoptose-inhibitor
DE69720957T2 (de) Ace-hemmer
NO974892L (no) Ventilasjonsr°r
MA26429A1 (fr) Inhibiteurs de protease
SI1047450T1 (en) Ace inhibitor-mmp inhibitor combinations
CY2007006I2 (el) Αναστολεις συνθεσεις απολιποπρωτεϊνης-β

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application